Innovative Emerging Molecular Analysis Technologies (SBIR R43/R44)

The summary for the Innovative Emerging Molecular Analysis Technologies (SBIR R43/R44) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Innovative Emerging Molecular Analysis Technologies (SBIR R43/R44): Purpose. This Funding Opportunity Announcement (FOA) solicits grant applications from small business concerns (SBCs) proposing research towards commercial development of emerging molecular and/or cellular analytical technologies intended for cancer detection and/or characterization. The goal of this FOA is to facilitate the translation of innovative, cancer-relevant technologies into commercial products and/or services. The emphasis is on molecular analysis technologies to improve cancer prevention, detection and diagnosis, surveillance, epidemiological research, and basic cancer research. These technologies may be intended for molecular and cellular analyses in vitro, in situ, and/or in vivo. There must be sound rationale pointing to the commercial potential of the technology to be developed. Mechanism of Support. This FOA will utilize the SBIR R43/R44 grant mechanisms for Phase I, Phase II, and Fast-Track applications. Funds Available and Anticipated Number of Awards. The estimated amount of funds available for support of five to seven projects awarded under this announcement is $2 million for fiscal year 2011. Future year amounts will depend on annual appropriations.

Federal Grant Title:	Innovative Emerging Molecular Analysis Technologies (SBIR R43/R44)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-10-013
Type of Funding:	Grant
CFDA Numbers:	93.393
CFDA Descriptions:	Cancer Cause and Prevention Research
Current Application Deadline:	Feb 08, 2011
Original Application Deadline:	Feb 08, 2011
Posted Date:	Sep 14, 2010
Creation Date:	Sep 14, 2010
Archive Date:	Mar 11, 2011
Total Program Funding:	$2,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Small businesses
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional); • Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required); • National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer ...; • Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Cli...; • Early-Stage Development of Informatics Technologies for Cancer Research and Management (U0...; • Pilot Studies in Pancreatic Cancer; • Cancer Prevention Research Small Grant Program; • Molecular Targets for Nutrients in Prostate Cancer Prevention
More Grants from the National Institutes of Health: • The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Preven...; • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional); • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...